Earnings Summary

Charles River Laboratories International’s revenue fell -7.85% since last year same period to $1013.48Mn in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated -1.28% fall in its revenue since last 3-months.

Charles River Laboratories International’s net profit fell -0.17% since last year same period to $187.08Mn in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated 114.08% jump in its net profits since last 3-months.

Charles River Laboratories International’s net profit margin jumped 8.33% since last year same period to 18.46% in the Q4 2023. On a quarterly growth basis, Charles River Laboratories International has generated 116.86% jump in its net profit margins since last 3-months.

Charles River Laboratories International’s earning per share (EPS) estimates for the current quarter stand at 2.07 - a -13.75% fall from last quarter’s estimates.

Charles River Laboratories International’s earning per share (EPS) estimates for the current year stand at 2.07.

Charles River Laboratories International’s earning per share (EPS) fell -17.45% since last year same period to 2.46 in the Q4 2023. This indicates that the Charles River Laboratories International has generated -17.45% annual rate of fall in its earning per share (EPS) in the last 4 quarters.